NCT02688075View on ClinicalTrials.gov

An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada

CompletedOBSERVATIONAL

Enrollment

538

Participants

Timeline

Start Date

November 13, 2015

Primary Completion Date

August 17, 2017

Study Completion Date

August 17, 2017

Conditions

Diabetes Mellitus, Type 2

Interventions

OTHER

No Intervention

Participants who are receiving Canagliflozin +/- other AHA as per usual clinical practice will be observed for effectiveness, safety and PRO.

Trial Locations (23)

Unknown

Calgary

Edmonton

Coquitlam

Surrey

Winnipeg

Brampton

Downsview

Guelph

London

Mississauga

Ohsweken

Ottawa

Smiths Falls

Toronto

Laval

Longueuil

Montreal

Saint-Jean-sur-Richelieu

Saint-Marc-des-Carrieres

Sherbrooke

Toronto

Westmont

Saskatoon

All Listed Sponsors

lead

Janssen Inc.

INDUSTRY

NCT02688075 - An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada | Biotech Hunter | Biotech Hunter